Clinical

Articles

AstraZeneca’s leading diabetes medication could be approved to treat chronic kidney disease for patients with and without type 2 diabetes.

Diabetes med Farxiga nabs FDA Priority Review for Chronic Kidney Disease

Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.

Two metformin products recalled, more on the way

How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.

Pharma exec: New type 2 diabetes treatment competitively priced

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

FDA clears first ready-to-use insulin for IV infusion

FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

FDA fast tracks blockbuster diabetes drug for heart failure

FDA fast-tracks biosimiliar insulin products to elevate competition.

Lack of insulin competition high priority for FDA

Eli Lilly launches generic insulin ahead of Congressional hearings

FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.

FDA clears novel diabetes, tropical disease therapies

FDA approves first long-term implantable glucose-monitoring system

Mayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.

Diabetes and Endocrinology